Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy

Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other a...

Descripción completa

Detalles Bibliográficos
Autor principal: Gallwitz, Baptist
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2016
Materias:
Diabetes Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813455/
https://www.ncbi.nlm.nih.gov/pubmed/29632584
http://dx.doi.org/10.17925/EE.2016.12.01.31
_version_ 1783300200336457728
author Gallwitz, Baptist
author_facet Gallwitz, Baptist
author_sort Gallwitz, Baptist
collection PubMed
description Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other antidiabetic agents that proved cardiovascular safety by non-inferiority compared with standard treatment with regard to a combined cardiovascular primary endpoint, empagliflozin showed superiority with a significantly lower incidence of cardiovascular events.
format Online
Article
Text
id pubmed-5813455
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Touch Medical Media
record_format MEDLINE/PubMed
spelling pubmed-58134552018-04-09 Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy Gallwitz, Baptist Eur Endocrinol Diabetes Editorial Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other antidiabetic agents that proved cardiovascular safety by non-inferiority compared with standard treatment with regard to a combined cardiovascular primary endpoint, empagliflozin showed superiority with a significantly lower incidence of cardiovascular events. Touch Medical Media 2016-03 2016-03-15 /pmc/articles/PMC5813455/ /pubmed/29632584 http://dx.doi.org/10.17925/EE.2016.12.01.31 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by/2.5/ This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
spellingShingle Diabetes Editorial
Gallwitz, Baptist
Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
title Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
title_full Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
title_fullStr Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
title_full_unstemmed Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
title_short Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
title_sort cardiovascular outcomes with empagliflozin – news for type 2 diabetes therapy
topic Diabetes Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813455/
https://www.ncbi.nlm.nih.gov/pubmed/29632584
http://dx.doi.org/10.17925/EE.2016.12.01.31
work_keys_str_mv AT gallwitzbaptist cardiovascularoutcomeswithempagliflozinnewsfortype2diabetestherapy

Ejemplares similares